Ahluwalia Contracts (India) Limited Board Approves Audited Financials and Recommends Dividend

Ahluwalia Contracts (India) Limited’s Board of Directors convened on May 30, 2026, to review and approve the audited financial results for the fourth quarter and the fiscal year ending March 31, 2026. The board also recommended a final dividend of 35% per equity share, subject to shareholder approval at the upcoming Annual General Meeting. Independent auditors have issued an unmodified opinion on the standalone and consolidated financial statements.

Board Meeting Highlights

Ahluwalia Contracts (India) Limited announced the outcome of its Board Meeting held on May 30, 2026. The meeting, which commenced at 4:00 PM and concluded at 5:15 PM, focused on the review and approval of key financial and strategic items.

Audited Financial Results Approved

The Board has considered and approved the Statement of Audited Financial Results, along with the Financial Statements (Standalone & Consolidated) for the Fourth Quarter and the Financial Year ended March 31, 2026. These results have been accompanied by the Auditors’ Report from independent auditors, M/s SCV & Co., LLP. The auditors have issued an unmodified opinion on the standalone and consolidated financial results.

Dividend Recommendation

A significant decision made by the Board was the recommendation of a final dividend. The rate proposed is 35% per equity share, translating to Re. 0.70 Paisa per share. This recommendation is contingent upon the approval of the shareholders at the forthcoming Annual General Meeting (AGM). The company will subsequently announce the date of the AGM and the payment date for the dividend, should it be approved.

Declaration on Unmodified Opinion

Furthermore, the Company has provided a declaration confirming the unmodified opinion on the Standalone and Consolidated Financial Results/Statements for the financial year ended March 31, 2026. This declaration has also been enclosed with the filing.

Financial Performance Overview (Standalone)

For the year ended March 31, 2026, Ahluwalia Contracts reported total income of ₹463,669.67 Lakhs. Total expenses amounted to ₹427,917.73 Lakhs, resulting in a Profit Before Exceptional Items and Tax of ₹35,751.94 Lakhs. After accounting for tax expenses, the Net Profit After Tax stood at ₹26,432.16 Lakhs. Basic Earnings Per Share (EPS) for the year was ₹39.46.

Consolidated Financial Performance

On a consolidated basis, for the year ended March 31, 2026, the Group reported total income of ₹463,671.68 Lakhs. Total expenses were ₹427,894.42 Lakhs, leading to a Profit Before Share of Profit/(Loss) from Joint Venture, exceptional items and tax of ₹35,777.26 Lakhs. The consolidated Net Profit After Tax for the year was ₹26,586.34 Lakhs. The consolidated Basic EPS was reported at ₹39.69.

Segment-wise Performance

The company operates primarily in two segments: Contract Work and Investment Property. For the year ended March 31, 2026, Segment Revenue from Contract Work was ₹455,894.69 Lakhs (Standalone) and ₹455,894.69 Lakhs (Consolidated). Segment Results from Contract Work were ₹37,125.28 Lakhs (Standalone) and ₹37,157.29 Lakhs (Consolidated).

Statement of Assets and Liabilities

As of March 31, 2026, total assets stood at ₹426,586.77 Lakhs (Standalone) and ₹426,485.52 Lakhs (Consolidated). Total Equity was ₹205,996.14 Lakhs (Standalone) and ₹205,890.37 Lakhs (Consolidated). Total Liabilities amounted to ₹220,590.63 Lakhs (Standalone) and ₹220,595.16 Lakhs (Consolidated).

Statement of Cash Flows

For the year ended March 31, 2026, Net Cash flow from operating activities was ₹28,127.56 Lakhs (Standalone). Net Cash flow used in investing activities was (₹25,721.58) Lakhs (Standalone). Net cash flow from financing activities was (₹3,428.99) Lakhs (Standalone). The net increase in Cash & Cash Equivalents for the year was (₹1,023.01) Lakhs (Standalone).

Other Disclosures

The results are available on the company’s website at www.acilnet.com and also on the websites of BSE and NSE.

Source: BSE

Previous Article

AstraZeneca Pharma India Receives Approval for Enhertu® for Additional Breast Cancer Indication

Next Article

Clean Science and Technology Limited Director Sanjay Kothari Resigns